Rasagilin at ALS (Phase II)

The neuroprotective potential of rasagiline, a monoamine oxidase B inhibitor, is already known from Parkinson's research and was also positively assessed in an ALS mouse model. In order to examine the effect of a daily dose of rasagiline with simultaneous administration of riluzole, a total of more than 250 patients were recruited for a study. Positive effects of the treatment could be observed in patients with rapidly progressing ALS; the drug was also well tolerated. The results were published in Lancet Neurology in 2018.